Participated · Series C · Dec 2019

Raziel Therapeutics is developing RZL-012, a proprietary new chemical entity intended as a single-injection treatment into subcutaneous fat for submental fat reduction and fat disorders such as Dercum’s disease. The company is clinical-stage and recently secured financing to advance development. It raised $22m in a Series C financing to support Phase 2b development of RZL-012 for submental fat reduction and Dercum’s disease. Raziel received FDA orphan drug designation for RZL-012 for Dercum’s disease on November 19 and plans to initiate a Phase 2b Dercum’s study in Q2 2020. If the Phase 2b study is successful, the company could pursue an NDA filing as soon as 2021. Leadership includes CEO Alon Bloomenfeld and newly appointed Chairman Philippe Schaison.

Participated · Series B · Sep 2013

SimilarWeb is an Israeli startup offering an AI-based platform that helps sites and apps track and analyze traffic for themselves and competitors. The platform uses machine learning and deep learning to surface not just visit counts but the "why" behind activity by aggregating multiple signals. Its customer base includes more than half of the Fortune 100, with clients such as Walmart, P&G, Adidas and Google. The company plans to use new funding for acquisitions and internal R&D to expand analytics services for larger enterprises and has launched an advisory service to work directly with large customers. SimilarWeb has around 600 employees today and intends to add roughly 200 more by January. Financially, it raised $120M in the latest round, has previously taken on some debt via Israel’s Paycheck Protection Program during the pandemic, and reported an $800M valuation in its last equity round in 2017. SimilarWeb provides analytics and competitive intelligence on website and app performance, covering about 80 million websites and three million apps across more than 190 countries. Its platform is offered on a freemium basis via a dashboard and API, and more than half of the Fortune 100 use its products alongside customers such as Google, eBay, Airbnb and Staples. The company emphasizes deeper engagement and conversion metrics rather than basic traffic counts, aiming to differentiate from incumbents like Nielsen and specialists such as App Annie and Apptopia. SimilarWeb has made acquisitions (three to date, including Quettra in 2015) to broaden its data ingestion and analytics capabilities. Management says it may expand into consulting to help clients act on its intelligence. The business plans to use new funding to continue building analytics, pursue business development and make further acquisitions. SimilarWeb provides websites and mobile app publishers with competitive traffic and market-intelligence analytics. Its platform collects anonymized traffic data from over 100 million devices and hundreds of thousands of sites, and analyzes that data with roughly 5,000 software components to produce competitive and market insights. The company began in 2007 as a Firefox plugin and pivoted in 2013 to the current analytics business. SimilarWeb sells a paid Pro tier (starting at $200/month) and reports revenues in the tens of millions with thousands of paying customers, including clients such as Flipkart and eBay; enterprise deals have scaled up to as much as $500,000 per month. Plans for the funding include hiring more engineers in Ukraine and Israel and expanding sales and account-management teams in New York, London and elsewhere. The company also announced a new CFO, Jason Schwartz. SimilarWeb is an online traffic-measurement company and Alexa competitor that provides website analytics across some 60 countries. The company is expanding into mobile analytics and app engagement measurement, tracking metrics such as app opens, session length, return frequency, churn, and affinity. To establish a mobile footprint it is building a portfolio of mobile apps and buying data from partners, and it has already moved into app store analytics and mobile web measurement for the U.S. and U.K. SimilarWeb operates from Tel Aviv with offices in London and Dubai, resellers in Russia, Brazil and Japan, and plans to open a New York office. Its paid service starts at $200/month for small firms and scales to enterprise offerings, while some data remains free. The company reports double-digit month-over-month growth in both revenue and customers, has a team of almost 100 employees, and is preparing a beta for its mobile app engagement product while planning acquisitions to accelerate mobile capabilities. SimilarGroup's core product, SimilarWeb, provides web-traffic measurement and rankings derived from a network of unbranded browser plug-ins and apps that produce a panel of tens of millions of end users. The company emphasizes data science and machine-learning to improve measurement accuracy and has launched a paid tier, SimilarWeb Pro, which has scaled to thousands of paying customers including eBay and Outbrain. Historically known for branded browser plug-ins (SimilarWeb, SimilarSites), the firm operates many unbranded extensions and mobile apps (data compression, browser speed, safe browsing, proxy services) to collect signals without disclosing their ownership. SimilarGroup is expanding into mobile app analytics, aiming to match websites to app counterparts and measure whether app traffic is paid or organic and user engagement. The company has a team of about 60 and is rapidly growing sales and international presence, with offices in London, upcoming Germany and New York openings, and plans to double its sales team. Financially, it has raised prior seed through Series B rounds totaling $7.1 million and has just closed a Series C from Naspers (size and valuation not officially disclosed; TechCrunch reports it is significant—"in the tens of millions").

Participated · Series E · Nov 2012

EarlySense, led by CEO Avner Halperin, develops contact-free continuous monitoring solutions used worldwide across the care continuum. Its FDA-cleared and CE-approved systems are deployed in hospitals, post-acute facilities and homes to assist clinicians in early detection of patient deterioration. The technology leverages artificial intelligence and big data analytics to deliver actionable health insights. EarlySense says its solutions have been proven to help prevent adverse events including code blue events, preventable ICU transfers, patient falls, pressure ulcers and hospital readmissions. The company is headquartered in Ramat Gan, Israel and Woburn, Massachusetts, and recently completed a $39M financing round. EarlySense provides an FDA-cleared and CE-approved contact-free continuous monitoring system that tracks patient heart rate, respiratory rate and movement via a sensor placed under the mattress. Continuous data is displayed on bedside monitors, nurse monitoring stations and delivered to clinicians’ smart devices. The company’s technology leverages Big Data and advanced algorithms to generate accurate health information for early detection of adverse events and improved patient outcomes. Its sensor technology also powers consumer products including Samsung’s SleepSense, iFit’s Sleep Sensor and Beurer’s SE 80 Sleep Expert. The company intends to use the new funding to continue to grow and to launch consumer digital health offerings based on its proven technology. EarlySense was founded in 2004 and is led by CEO Avner Halperin, with operations in Waltham, MA and Ramat Gan, Israel. EarlySense has developed a platform based on algorithms, analytics and smart Health/IT capabilities for contact-free, continuous monitoring of heart and respiratory rate, as well as movement and sleep. The system is installed in hospitals, rehabilitation centers and homes across the USA, Europe, Asia and Australia. EarlySense also offers OEM solutions for companies looking to add contact-free and continuous sensing capabilities to their products. The company is led by CEO Avner Halperin and has US headquarters in Waltham, MA while being based in Ramat Gan, Israel. EarlySense completed a $20M financing and intends to use the funds to continue to expand operations. EarlySense is described as the market leader in proactive patient care solutions, with a flagship contact‑free system that monitors and documents patients' vital signs and movement via a sensor placed beneath a mattress. The system requires no leads or cuffs, allowing patients freedom of movement, and is designed primarily for non‑ICU 'lower risk' patients on medical‑surgical floors. EarlySense's technology is installed in hospitals and rehabilitation centers across the U.S. and Europe and is commercially available in Canada. The company plans to use new financing to accelerate sales, further develop its contact‑free monitoring solutions, expand clinical research, and support global commercialization efforts. EarlySense is headquartered in Waltham, MA. EarlySense commercializes an automatic, continuous, contact-free patient monitoring system that documents vital signs and movement without leads or cuffs. The system is installed in hospitals and rehabilitation centers in the USA and Europe and is commercially available in Canada. Management and new board member Peter Soderberg see opportunities for rapid market growth initially in hospital and long‑term care markets and subsequently in the home market. The company recently received new innovative technology status from Novation and published clinical results from a Dignity Health study with Harvard‑affiliated support showing improved clinical outcomes. EarlySense is headquartered in Waltham, MA and lists investors including JK&B, Pitango Venture Capital, Etgar Challenge Fund, ProSeed VC Fund (TASE: PRSD), Docor International Management, Noaber, and Bridge Investment Fund. The press release does not disclose operating metrics such as revenue or user counts.